New Strategies for the Treatment of Advanced-Stage Hodgkin's Lymphoma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 897-914

  Diehl, Volker ^a   Engert, Andreas ^a   Re, Daniel ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LAPAROTOMY; LEUKEMIA; LUNG DISEASE; LYMPHOMA; MATHEMATICAL MODEL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SECOND CANCER; SIDE EFFECT; STEM CELL TRANSPLANTATION; STOMATITIS; THROMBOCYTE TRANSFUSION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 34748901297     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.07.004     Document Type: Review

References (35)

1. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 5 (2007) 579-586
2. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. [see comments]. N Engl J Med 339 21 (1998) 1506-1514
3. Hasenclever D., Loeffler M., and Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 7 Suppl 4 (1996) 95-98
4. DeVita V.J., Simon R.M., and Hubbard S.M. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92 (1980) 587-595
5. Bonadonna G., Zucali R., Monfardini S., et al. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36 1 (1975) 252-259
6. Santoro A., Bonadonna G., and Valagussa P. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5 (1987) 27-37
7. Canellos G., Anderson J., Propert K., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. [see comments]. N Engl J Med 327 21 (1992) 1478-1484
8. Viviani S., Bonadonna G., Santoro A., et al. Alternating versus hybrid and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 14 5 (1996) 1421-1430
9. Glick J.H., Young M.L., Harrington D., et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 16 1 (1998) 19-26
10. Klimo P., and Connors J. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3 9 (1985) 1174-1182
11. Connors J., Klimo P., Adams G., et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. [published erratum appears in J Clin Oncol 1997 Jul; 15(7):2762]. J Clin Oncol 15 4 (1997) 1638-1645
12. Duggan D., Petroni G., Johnson J., et al. A randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
13. Horning S.J., Hoppe R.T., Breslin S., et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20 3 (2002) 630-637
14. Advani R., Ai W.Z., and Horning S.J. Management of advanced stage Hodgkin lymphoma. J Natl Compr Canc Netw 4 3 (2006) 241-247
15. Gobbi P.G., Levis A., Chisesi T., et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23 36 (2005) 9198-9207
16. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 24 (2003) 2386-2395
17. Sieber M., Bredenfeld H., Josting A., et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 9 (2003) 1734-1739
18. Richards M., Waxman J., Man T., et al. EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 18 1 (1986) 51-53
19. Brizel D.M., Gockerman J.P., Crawford J., et al. A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. Cancer 74 1 (1994) 159-163
20. Canellos G.P., Gollub J., Neuberg D., et al. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 14 2 (2003) 268-272
21. Friedmann A.M., Hudson M.M., Weinstein H.J., et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20 14 (2002) 3088-3094
22. Chopra R., McMillan A., Linch D., et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81 5 (1993) 1137-1145
23. Horning S., Chao N., Negrin R., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89 3 (1997) 801-813
24. Reece D., Barnett M., Connors J., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9 10 (1991) 1871-1879
25. Federico M., Bellei M., Brice P., et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 12 (2003) 2320-2325
26. Hoppe R. Hodgkin's disease-the role of radiation therapy in advanced disease. Ann Oncol 7 Suppl 4 (1996) 99-103
27. Prosnitz L., Wu J., and Yahalom J. The case for adjuvant radiation therapy in advanced Hodgkin's disease. Cancer Invest 14 4 (1996) 361-370
28. Loeffler M., Brosteanu O., Hasenclever D., et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. [see comments]. J Clin Oncol 16 3 (1998) 818-829
29. Mauch P. What is the role for adjuvant radiation therapy in advanced Hodgkin's disease?. [editorial; comment]. J Clin Oncol 16 3 (1998) 815-817
30. Wirth A., Corry J., Laidlaw C., et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. [see comments]. Int J Radiat Oncol Biol Phys 39 3 (1997) 599-607
31. Pezner R., Lipsett J., Vora N., et al. Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval. Int J Radiat Oncol Biol Phys 30 4 (1994) 965-970
32. Diehl V., Loeffler M., Pfreundschuh M., et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). Ann Oncol 6 9 (1995) 901-910
33. Aleman B.M., Raemaekers J.M., Tirelli U., et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 24 (2003) 2396-2406
34. Diehl V. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood 104 11 (2004) 3071
35. Mauch P., Ng A., Aleman B., et al. Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl 66 (2005) 68-76